ID   451Lu-MR
AC   CVCL_DG54
DR   cancercelllines; CVCL_DG54
DR   GEO; GSM1199179
DR   Progenetix; CVCL_DG54
DR   Wikidata; Q54603182
RX   PubMed=24055054;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_75998; Trametinib (Mekinist; GSK1120212).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu61fs*59 (c.179dupC) (p.Gly75fs, c.222dupC); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Arm, skin; UBERON=UBERON_0002427.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6357 ! 451Lu
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 14
//
RX   PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023; PMCID=PMC3956616;
RA   Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M.,
RA   Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A.,
RA   Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K.,
RA   DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C.,
RA   Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X.-W.,
RA   Schuchter L.M., Herlyn M., Nathanson K.L.;
RT   "Concurrent MEK2 mutation and BRAF amplification confer resistance to
RT   BRAF and MEK inhibitors in melanoma.";
RL   Cell Rep. 4:1090-1099(2013).
//